Table 2. Univariate analysis of patients treated with chemotherapy in Cohort 1 (N=172).

Factor	No. of patients	No. alive	Hazard ratio (95% CI)	P-value
Gender
Female	28	6	Baseline
Male	144	36	0.66 (0.41–1.04)	0.075
Age, in years
⩽54	78	23	Baseline
46–65	84	16	1.31 (0.92–1.88)	0.14
>65	10	3	1.79 (0.81–3.96)	0.15
Albumin, g l −1
⩾04	32	10	Baseline
<40	128	31	1.43 (0.89–1.88)	0.13
Haemoglobin, g dl −1
⩾12	63	28	Baseline
<12	106	14	2.61 (1.76–3.87)	<0.001
ECOG status a
0–1	151	41	Baseline
2	14	1	2.24 (1.26–4.00)	0.006
3–4	7	0	4.19 (1.93–9.18)	<0.001
Leucocyte count, × 109 l−1
<4	26	4	Baseline
4–11	112	35	0.77 (0.48–1.24)	0.29
>11	31	3	1.46 (0.83–2.56)	0.19
UICC/AJCC stage at first diagnosisb
I–II	37	8	Baseline
III–IVB	86	23	1.21 (0.78–1.89)	0.38
IVC	33	9	1.41 (0.81–2.45)	0.22
Bone metastasis
No	42	10	Baseline
Yes	118	27	1.24 (0.82–1.85)	0.3
Liver metastasis
No	97	26	Baseline
Yes	74	16	1.60 (1.13–2.28)	0.008
Lung metastasis
No	106	27	Baseline
Yes	65	15	1.19 (0.83–1.70)	0.35
Distal node metastasis
No	107	19	Baseline
Yes	63	22	0.81 (0.56–1.18)	0.27
Number of metastatic sites
Single	69	17	Baseline
Multiple	103	25	1.55 (1.08–2.21)	0.017
Disease-free interval
>6 months	125	32	Baseline
⩽6 months	11	1	4.03 (2.02–8.02)	<0.001
Metastases at diagnosis	35	9	1.25 (0.81–1.94)	0.31

^aECOG status refers to performance status as defined by the Eastern Cooperative Oncology Group.

^bUICC/AJCC refers to International Union against Cancer/American Joint Committee on Cancer.